Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
In vitro activity of propyl gallate-azole drug combination against fluconazole- and itraconazole-resistant Candida albicans strains
2001
New Beauvericins, Potentiators of Antifungal Miconazole Activity, Produced by Beauveria sp. FKI-1366: I. Taxonomy, Fermentation, Isolation and Biological Properties
2004 StandoutNobel
Itraconazole
1989
Characterization of Saccharomyces cerevisiae CYP61, Sterol Δ22-Desaturase, and Inhibition by Azole Antifungal Agents
1997
Calpinactam, a new anti-mycobacterial agent, produced by Mortierella alpina FKI-4905
2010 StandoutNobel
Funicone-related Compounds, Potentiators of Antifungal Miconazole Activity, Produced by Talaromyces flavus FKI-0076.
2002 StandoutNobel
CLINICAL RELEVANCE OF ANTIFUNGAL RESISTANCE
1997
Detection of Novel Secondary Metabolites
1991
Phenatic Acids A and B, New Potentiators of Antifungal Miconazole Activity Produced by Streptomyces sp. K03-0132
2005 StandoutNobel
Anti-CandidaDrugs — The Biochemical Basis for Their Activity
1987
Plant Sterol 14α-Demethylase Affinity for Azole Fungicides
2001
Cytochrome P450 complement (CYPome) of the avermectin-producer Streptomyces avermitilis and comparison to that of Streptomyces coelicolor A3(2)
2003 StandoutNobel
Itraconazole: an effective oral antifungal for onychomycosis
2001
Recent developments in pradimicin-benanomicin and triazole antibiotics
1997
Substrate recognition sites in 14α-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51
2001
The Amino Acid Residues Affecting the Activity and Azole Susceptibility of Rat CYP51 (Sterol 14-Demethylase P450)
2001
Fluconazole
1990
Inhibition of sterol 14 alpha-demethylation of Candida albicans with NND-502, a novel optically active imidazole antimycotic agent
1999
Emerging fungal resistance
2004
Curcumin: The story so far
2005 Standout
Essential Oils in Food Preservation: Mode of Action, Synergies, and Interactions with Food Matrix Components
2012 Standout
Selectivity of Microbial Acyl-CoA : cholesterol Acyltransferase Inhibitors toward Isozymes
2007 StandoutNobel
Echinocandin antifungal drugs
2003 Standout
Citridones, New Potentiators of Antifungal Miconazole Activity, Produced by Penicillium sp. FKI-1938
2005 StandoutNobel
Citrinamides, New Potentiators of Antifungal Miconazole Activity, Produced by Penicillium sp. FKI-1938
2008 StandoutNobel
Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development
1998
Endocrine and Antitumoral Effects of R76713 in Rats
1990
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
2001 Standout
Inhibition of Angiogenesis by the Antifungal Drug Itraconazole
2007
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† †This study was presented, in part, at the 37th ICAAC in Toronto, Canada, 28th September – 1st October 1997.
2001
New Insecticidal Antibiotics, Hydroxyfungerins A and B, Produced by Metarhizium sp. FKI-1079
2005 StandoutNobel
Oral Azole Drugs as Systemic Antifungal Therapy
1994
Voriconazole: A New Triazole Antifungal Agent
2003 Standout
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
2016 Standout
New Beauvericins, Potentiators of Antifungal Miconazole Activity, Produced by Beauveria sp. FKI-1366: II. Structure Elucidation
2004 StandoutNobel
Cyclodextrin-based pharmaceutics: past, present and future
2004 Standout
Siccanin Rediscovered as a Species-Selective Succinate Dehydrogenase Inhibitor
2009 StandoutNobel
In vitro and in vivo evaluation of antifungal agents
1989
Antifungal agents: An overview. Part II
1994
Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
1990 Standout
Itraconazole
1996
History of the development of azole derivatives
2004
Sespendole, a New Inhibitor of Lipid Droplet Synthesis in Macrophages, Produced by Pseudobotrytis terrestris FKA-25
2006 StandoutNobel
Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies
1996
Immunity to fungal infections
2011 Standout
Itraconazole cyclodextrin solution
1997
Molecular diversity of sterol 14α‐demethylase substrates in plants, fungi and humans
1998
Characterization of Ecdysteroid 26-Hydroxylase: An Enzyme Involved in Molting Hormone Inactivation
2000
P450 inhibitors of use in medical treatment: Focus on mechanisms of action
1995
Biological effects of essential oils – A review
2007 Standout
Antifungal agents: mechanisms of action
2003 Standout
Yaequinolones, New Insecticidal Antibiotics Produced by Penicillium sp. FKI-2140
2006 StandoutNobel
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans
1997
Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase.
2002 Standout
Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications
2015 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Isolation and Identification of Actinobacteria from Surface-Sterilized Wheat Roots
2003 Standout
Identification of Farnesoid X Receptor β as a Novel Mammalian Nuclear Receptor Sensing Lanosterol
2003 StandoutNobel
Antifungal agents: chemotherapeutic targets and immunologic strategies
1996
Mechanism of Fluconazole Resistance in Candida krusei
1998
Nuclear Receptors and Lipid Physiology: Opening the X-Files
2001 StandoutScience
Characterization of an azole-resistant Candida glabrata isolate
1992
Activity of Orally, Topically, and Parenterally Administered Itraconazole in the Treatment of Superficial and Deep Mycoses: Animal Models
1987
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
1999 Standout
Structure and Total Synthesis of Fungal Calpinactam, A New Antimycobacterial Agent
2009 StandoutNobel
Initial Experience in Therapy for Progressive Mycoses with Itraconazole, the First Clinically Studied Triazole
1987
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Current and Emerging Azole Antifungal Agents
1999 Standout
Targeted Short-Term Fluconazole Prophylaxis Among Very Low Birth Weight and Extremely Low Birth Weight Infants
2006
Itraconazole
2000
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
1995
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
1998
Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance
1996
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole
1994
Characterization of Mechanisms of Fluconazole Resistance in a Candida albicans Isolate from a Japanese Patient with Chronic Mucocutaneous Candidiasis
2004
Aspergillus fumigatusand Aspergillosis
1999 Standout
Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B
1995
High-Frequency, In Vitro Reversible Switching of Candida lusitaniae Clinical Isolates from Amphotericin B Susceptibility to Resistance
1999
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
Relationships between Respiration and Susceptibility to Azole Antifungals in Candida glabrata
2003
Total Synthesis of Citridone A
2011 StandoutNobel
Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum
1997
Sino‐Orbital and Cerebral Aspergillosis: Cure with Medical Therapy/Sino‐Orbital‐ und Zerebralaspergillose: Ausheilung durch medikamentöse Therapie
1987
Burn Wound Infections
2006 Standout
Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients
2001
Fungicidal mechanism of action of D0870 against Cryptococcus neoformans under acidic conditions
1997
Pharmacology of Itraconazole
2001
Characteristics of the heterologously expressed human lanosterol 14α-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human andCandida albicans CYP51 with azole antifungal agents
1999
Enhanced inhibitory effect from interaction of curcumin with amphotericin B or fluconazole against Candida species
2020
Guidelines for Treatment of Candidiasis
2004 Standout
Comparative effects of the azole-based fungicide flusilazole on yeast and mammalian lanosterol 14 alpha-methyl demethylase
1989
Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
1997
Hidden Killers: Human Fungal Infections
2012 Standout
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
1995 Standout
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
1997
Drug Resistance in Leishmaniasis
2006 Standout
In Vitro Activities of Terbinafine against Cutaneous Isolates ofCandida albicansand Other Pathogenic Yeasts
1998
Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes
1996
Works of J. Gorrens being referenced
Mode of Action Studies: Basis for the Search of New Antifungal Drugs
1988
Saperconazole: A selective inhibitor of the cytochrome P‐450‐dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes
1990
Origin of differences in susceptibility of Candida krusei to azole antifungal agents
1995
Biochemical Approaches to Selective Antifungal Activity. Focus on Azole Antifungals
1989
Culture Media for the Study of the Effects of Azole Derivatives on Germ Tube Formation and Hyphal Growth of C. albicans/Nährböden zur Untersuchung der Wirkungen von Azolderivaten auf die Keimschlauchbildung und das Hyphenwachstum bei C. albicans
1986
Cytochrome p‐450: Target for itraconazole
1986
Effects of ketoconazole and itraconazole on growth and sterol synthesis in Pityrosporum ovale
1986
Interaction of azole derivatives with cytochrome P‐450 isozymes in yeast, fungi, plants and mammalian cells
1987
The action of itraconazole and ketoconazole on growth and sterol synthesis inAspergillus fumigatusandAspergillus niger
1985
Mutation in cytochrome P-450-dependent 14α-demethylase results in decreased affinity for azole antifungals
1990
Biochemical basis for the activity and selectivity of oral antifungal drugs.
1990
Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans
1993
The action of itraconazole and ketoconazole on growth and sterol synthesis in Aspergillus fumigatus and Aspergillus niger.
1985